Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative alanyl-glutamine infusion for glycemic control in uncontrolled diabetes during urgent coronary artery bypass surgery
PACTR202303692483097Phase 3Completed
- Sponsor
- Cardiothoracic Academy
- Start
- Jul 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of alanyl glutamine in diabetes mellitus (DM) and coronary arteriosclerosis (2 arms), sponsored by Cardiothoracic Academy. Primary endpoint: Mean intraoperative glucose level. Started Jul 2022; status: completed.
02
Drugs
alanyl glutamine
03
Conditions
diabetes mellitus (DM)coronary arteriosclerosis
Beyond the preview
Go deeper on PACTR202303692483097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202303692483097.